Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →BioNTech expanded its antibody-drug conjugate portfolio through a deal with China's Duality Biologics, bringing in HER2-targeting DB-1303 and…
Germany's BioNTech said on Monday it had signed a deal worth up to $1.7 billion with Chinese biotech Duality Biologics to develop antibody-drug conjugates for…
China's NMPA accepted a BLA for trastuzumab pamirtecan (T-Pam; DB-1303/BNT323) for 2L unresectable/metastatic HER2-positive breast cancer, based on the Phase…
Source summaries from our enrichment pipeline; follow links for originals.
All 14 sources with sentiment breakdown →
In April 2023 BioNTech and Duality Biologics (DualityBio) formed a global strategic partnership giving BioNTech development and commercialization rights (ex-Greater China) to two clinical-stage topoisomerase-1-inhibitor antibody-drug conjugates from DualityBio's DITAC platform: HER2-directed DB-1303 (BNT323) and B7-H3-directed DB-1311 (BNT324). DualityBio received $170M upfront plus up to ~$1.5B in development, regulatory and commercial milestones and tiered royalties (~$1.7B headline value). On August 7, 2023 the alliance was expanded to add a third ADC, the TROP2-directed DB-1305 (BNT325). The lead asset, DB-1303/BNT323 (INN trastuzumab pamirtecan, 'T-Pam'), has since de-risked materially: FDA granted Breakthrough Therapy Designation in advanced endometrial cancer (Dec 2023); the China Phase 3 DB-1303-O-3001 trial met its primary PFS endpoint in 2L HER2-positive metastatic breast cancer versus T-DM1 (Sep 2025); China's NMPA accepted a BLA for that indication (Apr 9, 2026); and a US FDA BLA in pretreated endometrial cancer is planned for later in 2026. The B7-H3 ADC DB-1311/BNT324 has advanced into a Phase 3 trial in metastatic castration-resistant prostate cancer (BNT324-03, vs docetaxel) and holds FDA Fast Track designation in mCRPC.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| BioNTech SE / Duality Biologics (Suzhou) Co. Ltd. (this deal) | 2023 | $1.7B | — |
| BioNTech SE / Biotheus Inc. (Pumai Biotechnology) | 2024 | $950M | — |
| BioNTech SE / Kite Pharma (Gilead Sciences) | 2021 | $250M | — |
| BioNTech SE / CureVac N.V. | 2025 | $1.2B | — |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| Novartis AG / Endocyte, Inc. | 2018 | $2.1B | 96 |
| Astellas Pharma Inc. / Seagen Inc. | 2009 | $4.5B | 95 |
← Browse all deals · How we score deals
More: 2023 deals · BioNTech SE deals · Oncology deals